Enterprise Therapeutics wins EMA orphan designation for cystic fibrosis drug

Enterprise Therapeutics has secured European orphan medicinal product designation for ETD001, an investigational inhaled therapy targeting mucus congestion in cystic fibrosis.

Enterprise Therapeutics has received European Medicines Agency (EMA) orphan medicinal product designation for ETD001, an investigational inhaled therapy being developed to treat cystic fibrosis (CF).

The designation follows positive Phase 2 results for the epithelial sodium channel (ENaC) blocker, which is designed to improve mucus clearance and reduce airway obstruction.

The EMA’s Committee for Orphan Medicinal Products (COMP) concluded that ETD001 met the criteria for orphan designation, recognising the rarity of cystic fibrosis and the potential for the treatment to provide clinically relevant benefit.

The decision is particularly relevant to people who cannot benefit from CFTR modulator therapies, which target the underlying genetic defect responsible for the disease. Enterprise is developing ETD001 as an additional treatment option for this patient population.

The recommendation was supported by clinical data from the Phase 2 ET-ENAC-03 study, which indicated an improvement in lung function. The company announced positive results earlier in 2026, although the latest announcement does not provide numerical efficacy or safety data.

Targeting mucus congestion in cystic fibrosis

Cystic fibrosis is a genetic disease that affects more than 100,000 people worldwide and can significantly reduce life expectancy.

The condition disrupts the movement of salt and water across cell membranes, resulting in thick, sticky mucus that is difficult to clear from the lungs. This contributes to recurrent infections, inflammation and progressive loss of lung function.

ETD001 is designed to block ENaC, a protein involved in regulating sodium absorption in airway cells. By reducing sodium absorption, the treatment aims to increase hydration on the airway surface, helping mucus move more effectively and supporting mucociliary clearance.

This approach differs from CFTR modulators, which are designed to address the defective CFTR protein responsible for cystic fibrosis. ETD001 is being developed to address mucus congestion, including in people who are not eligible for, or do not benefit from, CFTR modulator treatment.

Regulatory milestone for ETD001

Orphan medicinal product designation is intended to encourage the development of treatments for rare diseases where commercial incentives for research may otherwise be limited.

The designation can provide developers with regulatory and development incentives, including access to protocol assistance and potential market exclusivity following approval, subject to meeting the relevant requirements.

Dr John Ford, CEO of Enterprise Therapeutics, said: “Orphan drug designation represents an important regulatory milestone for the ETD001 programme and for Enterprise Therapeutics. The decision by the EMA reflects the continued need for additional treatment options for people with cystic fibrosis, particularly those who are not able to benefit from CFTR modulators. We look forward to continuing the development of ETD001 in CF as well as other mucus congestion related respiratory diseases.”

Annabella Amatulli, head of regulatory affairs at Enterprise Therapeutics, added: “Our regulatory strategy supports our global development plan for ETD001, aligned with our goal to provide improved therapeutic options for people with cystic fibrosis. The EMA’s orphan drug designation further validates the strength of the programme’s scientific rationale and outcomes of the Phase 2 clinical trial.”

The company plans to continue developing ETD001 for cystic fibrosis and other respiratory diseases associated with mucus congestion.

Mail Icon

news via inbox

Sign up for our newsletter and get the latest news right in your inbox